Revenue
$526.52M
Fiscal year ended 2025-12-31Operating income
$56.47M
Fiscal year ended 2025-12-31Free cash flow
$25.82M
Fiscal year ended 2025-12-31Core Laboratories Inc. /DE/ (CLB) reported revenue of $526.52M and net income of $29.67M for the fiscal year ended 2025-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Core Laboratories Inc. /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Oil & Gas Field Services, NEC.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $526.52M | $523.85M | $509.79M | $489.74M | $470.25M |
| Cost of revenue | $417.59M | $420.52M | $399.96M | $393.66M | Unavailable |
| Gross profit | $108.93M | $103.33M | $109.83M | $96.08M | Unavailable |
| Operating income | $56.47M | $58.56M | $54.64M | $41.52M | $45.26M |
| Net income | $29.67M | $31.40M | $36.68M | $19.45M | $19.73M |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 47.03M | shares 47.68M | shares 47.52M | shares 46.81M | shares 46.69M |
| Pretax income | $45.90M | $46.19M | $41.21M | $29.95M | $36.11M |
| Income tax expense | $15.50M | $14.03M | $4.18M | $10.30M | $15.89M |
| Diluted EPS | $0.63 | $0.66 | $0.77 | $0.42 | $0.42 |
| Selling, general & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| General & administrative | $45.43M | $39.77M | $40.26M | $38.12M | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cash & equivalents | $22.70M | $19.16M | $15.12M | $15.43M | Unavailable |
| Total assets | $584.01M | $585.13M | $586.40M | $578.35M | $580.85M |
| Current assets | $214.66M | $221.33M | $223.14M | $211.70M | Unavailable |
| Total liabilities | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Current liabilities | $106.02M | $102.44M | $88.10M | $103.14M | Unavailable |
| Total equity incl. NCI | $272.21M | $252.32M | $224.39M | $183.54M | $161.00M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $54.50M | $59.40M | $71.70M | $60.44M | Unavailable |
| Accounts receivable | $113.53M | $111.76M | $109.35M | $106.91M | Unavailable |
| Goodwill | $105.79M | $99.44M | $99.44M | $99.44M | Unavailable |
| Long-term debt | $110.26M | $126.11M | $163.13M | $172.39M | Unavailable |
| Accounts payable | $37.28M | $34.55M | $33.51M | $45.85M | Unavailable |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating cash flow | $37.03M | $56.39M | $24.79M | $24.96M | $36.58M |
| Capital expenditures | $11.21M | $11.89M | $10.58M | $10.22M | $13.54M |
| Investing cash flow | -$2.23M | -$6.39M | -$6.65M | -$3.86M | -$10.22M |
| Financing cash flow | -$31.26M | -$45.96M | -$18.44M | -$23.38M | -$22.46M |
| Net change in cash | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Stock-based compensation | $7.14M | $3.76M | $13.97M | $7.76M | $19.09M |
| Common dividends paid | $1.87M | $1.88M | $1.87M | $1.85M | $1.83M |
| Common share repurchases | $12.43M | $5.31M | $2.20M | $3.90M | $8.26M |
| Depreciation & amortization | $14.65M | $14.95M | $15.78M | $17.16M | $18.52M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free cash flow | $25.82M | $44.50M | $14.21M | $14.74M | $23.04M |
| Gross margin | 20.7% | 19.7% | 21.5% | 19.6% | Unavailable |
| Operating margin | 10.7% | 11.2% | 10.7% | 8.5% | 9.6% |
| FCF margin | 4.9% | 8.5% | 2.8% | 3.0% | 4.9% |
| SBC / revenue | 1.4% | 0.7% | 2.7% | 1.6% | 4.1% |
| Current ratio | 2.02x | 2.16x | 2.53x | 2.05x | Unavailable |
| Revenue YoY growth | 0.5% | 2.8% | 4.1% | 4.1% | Unavailable |
| Net margin | 5.6% | 6.0% | 7.2% | 4.0% | 4.2% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 2.1% | 2.3% | 2.1% | 2.1% | 2.9% |
| Long-term debt / equity | 0.41x | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 33.8% | 30.4% | 10.2% | 34.4% | 44.0% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CLB in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-01View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-10-23View SEC filing
10-Q · Filed 2025-07-25View SEC filing
10-Q · Filed 2025-04-28View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.